<DOC>
	<DOCNO>NCT00439244</DOCNO>
	<brief_summary>The purpose study assess effect zoledronic acid administer time teriparatide compare zoledronic acid alone teriparatide alone bone mineral density ( BMD ) gain lumbar spine total hip</brief_summary>
	<brief_title>Efficacy Study Zoledronic Acid Teriparatide Combination Therapy Women With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Inclusion criterion : Postmenopausal ( PMO ) woman 45 89 year age . Bone mineral density T score 2.5 less femoral neck , total hip lumbar spine OR Bone mineral density T score 2.0 less femoral neck , total hip lumbar spine least one document osteoporotic vertebral fracture previously document history osteoporotic clinical nonvertebral fracture due excessive trauma Exclusion criterion : Any prior use strontium Any past active kidney disease problem kidney function Prior treatment intravenous ( i.v . ) oral bisphosphonate ( limited alendronate , risedronate pamidronate ) long 3 month consecutively . If bisphosphonate exposure less equal 3 month , washout period 1 year randomization require Calcium level blood within normal range Normal liver function Nonosteoporotic form metabolic bone disease limit Paget 's disease bone , osteomalacia , osteogenesis imperfecta multiple myeloma Less 3 evaluable lumbar ( L1L4 ) vertebrae dual energy xray absorptiometry ( DXA ) measurement Treatment osteoporotic therapy raloxifene , calcitonin Hormone Replacement Therapy within 3 month randomization Allergy previous exposure teriparatide Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Bone Mineral Density ( BMD )</keyword>
	<keyword>C-Telopeptides ( CTx )</keyword>
	<keyword>dual x-ray absorptiometry ( DXA )</keyword>
	<keyword>pro-collagen type 1 N-propeptide ( P1NP )</keyword>
	<keyword>teriparatide</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>postmenopausal woman</keyword>
</DOC>